Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial.
Roerink, Megan E, Bredie, Sebastian J H, Heijnen, Michael et al. · Annals of internal medicine · 2017 · DOI
Quick Summary
Researchers tested whether a drug called anakinra, which reduces inflammation in the body, could help reduce fatigue in women with ME/CFS. Over 4 weeks, patients received either anakinra injections or placebo (dummy injections), and both groups were followed for an additional 20 weeks. The drug did not significantly improve fatigue or other symptoms compared to placebo, though some patients experienced injection site reactions.
Why It Matters
This study directly tests the hypothesis that IL-1-mediated inflammation drives ME/CFS fatigue, a theory supported by some immunological findings. A negative result suggests that peripheral IL-1 inhibition alone is insufficient to treat ME/CFS, which has implications for future therapeutic strategies and understanding of disease pathophysiology.
Observed Findings
Only 8% (2/25) of anakinra recipients vs. 20% (5/25) of placebo recipients achieved fatigue scores in the healthy range at 4 weeks.
Mean difference in CIS-fatigue score at 4 weeks was 1.5 points (95% CI: -4.1 to 7.2), not statistically or clinically significant.
Injection site reactions occurred in 68% (17/25) of anakinra recipients compared to 4% (1/25) of placebo recipients.
No significant between-group differences were observed for secondary outcomes (impairment, functioning, distress, pain) at 4 or 24 weeks.
One patient in the anakinra group discontinued due to an adverse event.
Inferred Conclusions
Peripheral IL-1 inhibition using anakinra for 4 weeks does not produce clinically meaningful fatigue reduction in women with CFS and severe fatigue.
The lack of efficacy suggests that short-term blockade of IL-1 alone is insufficient to address ME/CFS pathophysiology, or that IL-1 may not be a primary driver of fatigue in this population.
The safety profile and tolerability were poor relative to efficacy, with frequent injection site reactions limiting practical utility.
Remaining Questions
Would higher doses, longer treatment duration, or earlier intervention (closer to disease onset) yield different results?
What This Study Does Not Prove
This study does not prove that inflammation plays no role in ME/CFS—only that blocking IL-1 peripherally for 4 weeks does not reduce fatigue. The findings do not exclude central nervous system IL-1 involvement, other cytokine pathways, or the importance of inflammation in disease onset or maintenance. Additionally, heterogeneity in symptom duration and lack of restriction to postinfectious cases may have obscured effects in subgroups.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Are other cytokines (IL-6, TNF-α, IFN-γ) more relevant therapeutic targets than IL-1 in ME/CFS?
Does IL-1 inhibition benefit specific patient subgroups (e.g., postinfectious cases, those with elevated baseline IL-1 levels) not captured in this heterogeneous sample?
What is the role of central nervous system versus peripheral IL-1 in ME/CFS fatigue generation?